Across TCGA pan-cancer cohorts, KRTAP20-4 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of KRTAP20-4’s most consistent transcriptional readouts.

The strongest signal is observed in prostate adenocarcinoma (PRAD), where KRTAP20-4 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types KRTAP20-4 is over-expressed in tumor.

PRAD and LIHC are the cancer types where KRTAP20-4 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in KRTAP20-4 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PRAD	All	All	+0.522	.005	2	view →
LIHC	All	All	+0.174	.018	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: KRTAP20-4 RNA expression & survival · all KRTAP20-4 data types